Westlake Aging Cohort (WeAC)
Westlake Aging Cohort
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ju-Sheng Zheng, PhD
- Phone Number: 86-0571-86915303
- Email: zhengjusheng@westlake.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310058
- Recruiting
- Hangzhou First People's Hospital
-
Contact:
- Ju-Sheng Zheng, PhD
- Phone Number: 86-0571-86915303
- Email: zhengjusheng@westlake.edu.cn
-
Hangzhou, Zhejiang, China, 310058
- Recruiting
- Hangzhou Third People's Hospital
-
Contact:
- Peng Li, Master
-
Contact:
- Yu Chen, Master
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All participants must be Chinese residents, regardless of their ethnicity.
Description
Inclusion Criteria:
- Age between 55 and 90 years (inclusive) at baseline.
- Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
- Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
- MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
- Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
- Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.
Exclusion Criteria:
- Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
- Current use of psychoactive medications or any other drugs that may affect the study.
- Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
- Participants with any other diseases that may affect the study.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive function
Time Frame: 48 months
|
Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians. |
48 months
|
|
Gut microbiome
Time Frame: 48 months
|
The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified. |
48 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brain magnetic resonance imaging
Time Frame: 48 months
|
Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants. |
48 months
|
|
Positron emission tomography
Time Frame: 48 months
|
Assess the brain function and neurological disorders by positron emission tomography (PET). |
48 months
|
|
Brain images relevant inspections
Time Frame: 48 months
|
Other brain image relevant inspections required for study to measure brain structure and function of participants. |
48 months
|
|
Electroencephalogram
Time Frame: 48 months
|
Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking. |
48 months
|
|
Blood biochemical parameters
Time Frame: 48 months
|
Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer. |
48 months
|
|
Serum inflammatory factors
Time Frame: 48 months
|
Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants. |
48 months
|
|
Health and behavior monitoring
Time Frame: 48 months
|
Use fitness trackers to record the physiological and behavioral data of participants. |
48 months
|
|
Sleep data measurement
Time Frame: 48 months
|
Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality. |
48 months
|
|
Continuous glucose monitoring
Time Frame: 48 months
|
Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants. |
48 months
|
|
Environmental measurement
Time Frame: 48 months
|
Use the environmental monitoring device to measure various exposure factors in the participants' living environment. |
48 months
|
|
Multi-omics data
Time Frame: 48 months
|
Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc. |
48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ju-Sheng Zheng, PhD, Westlake University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20251023ZJS001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.